Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma

Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens

“…8 CD34 þ cell dose and outcome Several studies have evaluated the relation of CD34 þ cell dose and to patient outcome after auto-SCT. [16][17][18][19][20][21][22][23][24][25][26][27] These studies are summarised in Table 2. The general impression is that better blood stem-cell mobilization or a higher CD34 þ cell dose is associated with superior-outcome post transplant.…”

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

“…[1][2][3] Current data suggest that greater than 2.0 Â 10 6 CD34 þ cells/kg are needed to assure reliable and sustained hematopoietic recovery after auto-SCT. [4][5][6] Failure to transplant a sufficient number of hematopoietic stem cells can lead to delayed engraftment or graft failure. PBSCs are collected through apheresis after treatment with chemomobilization with cytokine support, usually G-CSF, or with mobilization using cytokine alone.…”

A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma

“…[14][15][16][17] Further, difficult SC mobilization predicts a poor outcome. Lastly, serious infections because of delayed B-cell recovery and late-onset neutropenia have been reported with post-transplant rituximab.…”